

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 1 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**IN THE TITLE PAGES:**

Item [56] References Cited, in OTHER PUBLICATIONS:


in Yudin, please replace "Geterotsikicheskikh" with --Geterotsiklicheskikh--  
in the first Yamashkin et al., please replace "Chemistry.of" with --Chemistry of--  
in Edwards, J., et al., please replace "(1999)" with --(1998)--  
in Boyer, M., please replace

"<http://www.australianprescriber.com/magazines/vol19no1/ap19-1-11.htm>(accessed on Jan. 28, 2005)." with --<http://www.australianprescriber.com/magazines/vol19no1/ap19-1-11.htm> (accessed on Jan. 28, 2005).--

in Castillo, P., please replace "o-dihydroxyaromatic" with --o-dihydroxyaromatic--


**IN THE SPECIFICATION:**

In column 2, beginning at line 7, please replace formulas I-VIII with:




(I)

OR




(II)

OR



(III)

OR



(IV)



OR

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION


PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 2 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:



in column 7, beginning at line 15, please replace formulas I-VIII with:




UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**


PATENT NO. : 7,026,484 B2  
 APPLICATION NO. : 10/080926  
 DATED : April 11, 2006  
 INVENTOR(S) : Lin Zhi et al.

Page 3 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:



in column 24, lines 53-67, please replace the structures in Scheme II with:



UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 4 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


in column 57, lines 4-6, please replace  
“(Compound 177, Structure 26 of Scheme IV, where  $R_2$ =methyl,  $R_3$ =2-hydroxyethyl”  
with --(Compound 177, Structure 26 of Scheme IV, where  $R_2$ =methyl,  $R_3$ =2-hydroxyethyl--

in column 70, line 21, please replace “chloronation” with --chlorination--


**IN THE CLAIMS:**

Please replace Claims 1, 4, 26, 28, 29, 30, 32, 33, 34, 42, 43, 50, 52, 53, and 60 with the following Claims:


1. A compound of the formula:




OR



OR



OR



UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 5 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

wherein:

R<sup>1</sup> is selected from among hydrogen, F, Cl, Br, I, NO<sub>2</sub>, OR<sup>12</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>R<sup>12</sup>, substituted C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl and C<sub>1</sub>-C<sub>8</sub> heteroalkyl, wherein the haloalkyl and heteroalkyl groups are optionally substituted;

R<sup>2</sup> is selected from among F, Cl, Br, I, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, CF<sub>2</sub>Cl, CN, CF<sub>2</sub>OR<sup>12</sup>, CH<sub>2</sub>OR<sup>12</sup>, OR<sup>12</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, substituted C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl and C<sub>2</sub>-C<sub>8</sub> alkynyl, wherein the haloalkyl, heteroalkyl, alkenyl and alkynyl groups are optionally substituted;

R<sup>3</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R<sup>4</sup> is selected from among hydrogen F, Cl, Br, I, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, heteroaryl and arylalkyl wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted;

R<sup>5</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R<sup>6</sup> is selected from among hydrogen F, Cl, Br, I, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted;

R<sup>7</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl, and heteroalkyl groups are optionally substituted;

R<sup>8</sup> is selected from among hydrogen F, Cl, Br, I, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted; or

R<sup>3</sup> and R<sup>5</sup> taken together form a bond; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>4</sup> and R<sup>6</sup> taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted; or

R<sup>6</sup> and R<sup>8</sup> taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted;

R<sup>9</sup> and R<sup>10</sup> each independently is selected from among hydrogen, F, Cl, Br, I, CN, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, C<sub>m</sub>(R<sup>12</sup>)<sub>2m</sub>OR<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>C(O)R<sup>13</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups are optionally substituted;

R<sup>11</sup> is selected from F, Br, Cl, I, CN, OR<sup>14</sup>, NR<sup>14</sup>R<sup>13</sup>, and SR<sup>14</sup>;

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 6 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

$R^{12}$  and  $R^{13}$  each independently is selected from the group of hydrogen,  $C_1$ - $C_8$  alkyl,  $C_1$ - $C_8$  haloalkyl,  $C_1$ - $C_8$  heteroalkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, heteroaryl and aryl wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted;

$R^{14}$  is selected from among hydrogen,  $C_1$ - $C_8$  alkyl,  $C_1$ - $C_8$  haloalkyl,  $C_1$ - $C_8$  heteroalkyl, aryl, heteroaryl,  $C(O)R^{15}$ ,  $CO_2R^{15}$  and  $C(O)NR^{15}R^{16}$ , wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups are optionally substituted;

$R^{15}$  and  $R^{16}$  each independently is selected from among hydrogen,  $C_1$ - $C_8$  alkyl,  $C_1$ - $C_8$  haloalkyl,  $C_1$ - $C_8$  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

W is O or S;

X is N  $\{R^{14}\}$ ;

Y is selected from among O, S, N  $\{R^{12}\}$  and NO  $\{R^{12}\}$ ;

Z is N  $\{R^{12}\}$ ;

n is 0; and

m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 1, wherein  $R^2$  is selected from among F, Cl, Br,  $CF_3$ ,  $CF_2Cl$ ,  $CF_2H$ ,  $CFH_2$ , substituted  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  heteroalkyl,  $C_2$ - $C_4$  alkenyl and  $C_2$ - $C_4$  alkynyl, wherein the haloalkyl, heteroalkyl, alkenyl and alkynyl groups are optionally substituted.

26. A compound according to claim 1, wherein:

$R^6$  and  $R^8$  each independently is selected from among hydrogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl,  $C_1$ - $C_6$  heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups are optionally substituted; or

$R^6$  and  $R^8$  taken together form a three to eight membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted.

28. A compound according to claim 1, wherein:

$R^1$  is selected from among hydrogen, F, Cl, Br, I, substituted  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl and  $C_1$ - $C_6$  heteroalkyl, wherein the haloalkyl and heteroalkyl groups are optionally substituted;

$R^2$  is selected from among F, Cl, Br,  $CF_3$ ,  $CF_2Cl$ ,  $CF_2H$ ,  $CFH_2$ , substituted  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl and  $C_1$ - $C_6$  heteroalkyl, wherein haloalkyl and heteroalkyl groups are optionally substituted; and

$R^3$  and  $R^4$  each independently is selected from among hydrogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl and  $C_1$ - $C_6$  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 7 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

29. A compound according to claim 28, wherein

R<sup>5</sup> through R<sup>8</sup> each independently is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or

R<sup>6</sup> and R<sup>8</sup> taken together form a four to six membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted.

30. A compound according to claim 29, wherein:

R<sup>9</sup> and R<sup>10</sup> each independently is selected from among hydrogen, F, Cl, Br, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R<sup>12</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted; and

R<sup>14</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C(O)R<sup>15</sup>, CO<sub>2</sub>R<sup>15</sup> and C(O)NR<sup>15</sup>R<sup>16</sup>, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted.

32. A compound according to claim 1, wherein said compound is selected from among:  
6-Methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Isopropyl-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Allyl-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-(4-Methoxyphenyl)-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-(3-Trifluoromethylphenyl)-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

4-Trifluoromethyl-5,6,7,8-tetrahydrocyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

4-Trifluoromethyl-5,6,7,8,9,10-hexahydrocycloheptano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[g]pyrrolo-[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-ethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]-quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-5,6-*cis*-dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-propyl-4-trifluoromethylcyclopentano-[g]pyrrolo-[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(3-furanylmethyl)-4-trifluoromethylcyclopentano[g]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(3-thiophenemethyl)-4-trifluoromethylcyclopentano[g]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 8 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2-methylpropyl)-4-trifluoromethylcyclopentano[g]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2,2,2-chlorodifluoro-ethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-cyclopropylmethyl-4-trifluoromethylcyclopentano[g]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2,2-dimethoxyethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,8,8a(*cis*)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9*H*-cyclohexano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,8,9,9a(*cis*),10-Octahydro-10-(2,2,2-trifluoroethyl)-4-trifluoromethylcycloheptano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-5-(4-nitrophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-5-(4-dimethylaminophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-methyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-5-(3-trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-5-(4-fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-Dihydro-5-phenyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo-3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2-dimethoxyethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-5-isopropyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo-[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo-[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-Dihydro-5-(2-ethoxycarbonyl-ethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;



UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 9 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5,6,7,8-Tetrahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano[g]-pyrrolo[3,2-f]quinolin-2(1H)-one;  
8-Trifluoroethyl-4-trifluoromethyl-6,8-dihydrocyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;  
9-Trifluoroethyl-trifluoromethyl-9H-benzo[g]pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-(3-Trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-(4-Fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-(2-Ethoxycarbonyl-ethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Methyl-6-(1-hydroxyethyl)-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Methyl-6-acetyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Formyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Acetyloxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
2-Acetyloxy-5-hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinoline;  
6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Ethoxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
(+)-6-(1-Methoxyethyl)-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
7-Allyl-6-methyl-4-trifluoromethyl-5H-pyrrolo[2,3-f]quinolin-2(1H)-one;  
6-Ethyl-7-methyl-4-trifluoromethyl-5H-pyrrolo[2,3-f]quinolin-2(1H)-one;

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 10 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

7-(3-Trifluoromethylphenyl)-6-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;  
7-(2-Hydroxyethyl)-6-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;  
(+)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethyl-cyclopentano-[*g*]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(-)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano-[*g*]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-Dihydro-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-Dihydro-7-ethyl-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
5-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
6-Formyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one; and  
5,6-Dimethyl-7-(2,2-difluorovinyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one.

33. A compound according to claim 1, wherein said compound is selected from the group consisting of:

(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano-[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-ethyl-4-trifluoromethylcyclopentano-[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-Dihydro-5,6-*cis*-dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-propyl-4-trifluoromethylcyclopentano-[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2,2,2-chlorodifluoroethyl)-4-trifluoromethylcyclopentano-[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-cyclopropylmethyl-4-trifluoromethylcyclopentano-[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-4*c*,5,6,7,8,8*a*(*cis*)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9*H*-cyclohexan[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-*cis*-Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-*cis*-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**





PATENT NO. : 7,026,484 B2  
 APPLICATION NO. : 10/080926  
 DATED : April 11, 2006  
 INVENTOR(S) : Lin Zhi et al.

Page 11 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-5,6-*cis*-Dihydro-5-methyl-6-ethyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-*f*]-quinolin-2(1*H*)-one;  
 5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
 6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
 6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
 5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
 5,6,7,8-Tetrahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[*g*]pyrrolo[3,2-*f*]-quinolin-2(1*H*)-one;  
 6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
 (+)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano-*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
 (-)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano-*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one.

34. A pharmaceutical composition, comprising:  
 a pharmaceutically acceptable carrier; and  
 a compound of formula:



UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 12 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

wherein:

R<sup>1</sup> is selected from among hydrogen, F, Cl, Br, I, NO<sub>2</sub>, OR<sup>12</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl and C<sub>1</sub>-C<sub>8</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R<sup>2</sup> is selected from among F, Cl, Br, I, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, CF<sub>2</sub>Cl, CN, CF<sub>2</sub>OR<sup>12</sup>, CH<sub>2</sub>OR<sup>12</sup>, OR<sup>12</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, substituted C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl and C<sub>2</sub>-C<sub>8</sub> alkynyl, wherein the haloalkyl, heteroalkyl, alkenyl and alkynyl groups are optionally substituted;

R<sup>3</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R<sup>4</sup> is selected from among hydrogen, F, Cl, Br, I, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted;

R<sup>5</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R<sup>6</sup> is selected from among hydrogen, F, Cl, Br, I, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted;

R<sup>7</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R<sup>8</sup> is selected from among hydrogen, F, Cl, Br, I, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted; or

R<sup>3</sup> and R<sup>5</sup> taken together form a bond; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>4</sup> and R<sup>6</sup> taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted; or

R<sup>6</sup> and R<sup>8</sup> taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted;

R<sup>9</sup> and R<sup>10</sup> each independently is selected from among hydrogen, F, Cl, Br, I, CN, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, C<sub>m</sub>(R<sup>12</sup>)<sub>2m</sub>OR<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>C(O)R<sup>13</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups are optionally substituted;

R<sup>11</sup> is selected from among hydrogen, F, Br, Cl, I, CN, OR<sup>14</sup>, NR<sup>14</sup>R<sup>13</sup> and SR<sup>14</sup>;

R<sup>12</sup> and R<sup>13</sup> each independently is selected from among hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted;

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 13 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R<sup>14</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, aryl, heteroaryl, C(O)R<sup>15</sup>, CO<sub>2</sub>R<sup>15</sup> and C(O)NR<sup>15</sup>R<sup>16</sup>, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups are optionally substituted;

R<sup>15</sup> and R<sup>16</sup> each independently is selected from among hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl and C<sub>1</sub>-C<sub>8</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

W is O or S;

X is N {R<sup>14</sup>};

Y is selected from among O, S, N{R<sup>12</sup>} and N{OR<sup>12</sup>};

Z is N{R<sup>12</sup>};

n is 0; and

m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

42. A pharmaceutical composition according to claim 34, wherein R<sup>11</sup> is selected from among F, Cl, CN, OR<sup>14</sup>, NR<sup>14</sup>R<sup>13</sup> and SR<sup>14</sup>.

43. A pharmaceutical composition according to claim 42, wherein R<sup>11</sup> is selected from among F, Cl, OR<sup>14</sup>, SR<sup>14</sup>, NR<sup>14</sup>R<sup>13</sup>.

50. A pharmaceutical composition according to claim 49, wherein:

R<sup>5</sup> through R<sup>8</sup> each independently is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or

R<sup>6</sup> and R<sup>8</sup> taken together form a four to six membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted.

52. A pharmaceutical composition according to claim 51 wherein Y is O or S.


UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,026,484 B2  
 APPLICATION NO. : 10/080926  
 DATED : April 11, 2006  
 INVENTOR(S) : Lin Zhi et al.

Page 14 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

53. A compound of formula:



wherein:

$R^1$  is selected from among hydrogen, F, Cl, Br, I,  $\text{NO}_2$ ,  $\text{OR}^{12}$ ,  $\text{SR}^{12}$ ,  $\text{SOR}^{12}$ ,  $\text{SO}_2\text{R}^{12}$ ,  $\text{NR}^{12}\text{R}^{12}$ ,  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_1\text{-C}_8$  haloalkyl and  $\text{C}_1\text{-C}_8$  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

$R^2$  is selected from among F, Cl, Br,  $\text{CF}_3$ ,  $\text{CHF}_2$ ,  $\text{CH}_2\text{F}$ ,  $\text{CF}_2\text{Cl}$ ,  $\text{CF}_2\text{OR}^{12}$ ,  $\text{CH}_2\text{OR}^{12}$ ,  $\text{OR}^{12}$ ,  $\text{SR}^{12}$ ,  $\text{SOR}^{12}$ ,  $\text{SO}_2\text{R}^{12}$ ,  $\text{NR}^{12}\text{R}^{13}$ , substituted  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  haloalkyl and  $\text{C}_1\text{-C}_6$  heteroalkyl, wherein the haloalkyl, and heteroalkyl groups are optionally substituted;

$R^3$  is selected from among hydrogen,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  haloalkyl and  $\text{C}_1\text{-C}_6$  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

$R^4$  is selected from among hydrogen,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  haloalkyl and  $\text{C}_1\text{-C}_6$  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

$R^5$  is selected from among hydrogen,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  haloalkyl and  $\text{C}_1\text{-C}_6$  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 15 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R<sup>6</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups are optionally substituted;

R<sup>7</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R<sup>8</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups are optionally substituted; or

R<sup>3</sup> and R<sup>5</sup> taken together form a bond; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>4</sup> and R<sup>6</sup> taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted;

R<sup>6</sup> and R<sup>8</sup> taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted;

R<sup>9</sup> and R<sup>10</sup> each independently is selected from among hydrogen, F, Cl, Br, I, CN, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, C<sub>m</sub>(R<sup>12</sup>)<sub>2m</sub>OR<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>C(O)R<sup>13</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups are optionally substituted;

R<sup>11</sup> is selected from among F, Br, Cl, I, CN, OR<sup>14</sup>, NR<sup>14</sup>R<sup>13</sup> and SR<sup>14</sup>;

R<sup>12</sup> and R<sup>13</sup> each independently is selected from among hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted;

R<sup>14</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, aryl, heteroaryl, C(O)R<sup>15</sup>, CO<sub>2</sub>R<sup>15</sup> and C(O)NR<sup>15</sup>R<sup>16</sup>, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups are optionally substituted;

R<sup>15</sup> and R<sup>16</sup> each independently is selected from among hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl and C<sub>1</sub>-C<sub>8</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

W is O or S;

X is N {R<sup>14</sup>};

Y is selected from among O, S, N {R<sup>12</sup>} and NO {R<sup>12</sup>};

Z is N {R<sup>12</sup>};

n is 0; and

m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 16 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

60. A compound according to claim 34, wherein:


R<sup>5</sup> and R<sup>7</sup> each independently is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond.

This certificate supersedes Certificate of Correction issued October 31, 2006.

Signed and Sealed this

Twenty-seventh Day of February, 2007

A handwritten signature in black ink, appearing to read "Jon W. Dudas", is written over a faint, circular embossed seal of the United States Patent and Trademark Office.

JON W. DUDAS  
*Director of the United States Patent and Trademark Office*